Glactone Pharma Development Ab

Gedea Biotech Ab

Laccure Ab

Bayer Aktiengesellschaft

Innovationspatent Sverige Ab

Denovastella Ab

Everest Biosciences, Inc.

Boehringer Mannheim Gmbh

Adenovir Pharma Ab

Ambria Dermatology Ab

Gabather Ab

Oncorel Ab

Olov Sterner

Martin Johansson

Thomas Hedner

Ulf Ellervik

Helena Strevens

Sophie Manner

Werner Schubert

Heidrun Anke

Joergen Johnsson

Greg Batcheller

Christer Sjoegren

Malgorzat Sznitowska

Michael Kilian

Jakob Nilsson

Rikard Larsson

Mogens Peter Cherly Nielsen

Tommy Liljefors

Jenny Persson

Ulrike Wachendorff-Neumann

Peter Jeschke

Achim Harder

Anders Carlsson

Wolfgang Gau

Nils-Olof Lindberg

Winfried Etzel

Jan Faergemann

Jörgen Johnsson

Liesel Dorge

R&uuml;diger Hain

Fritz Hansske

Anders Bjartell

Karolina Aplander

Lars Bjork

Per-Olof Remberg

Lars-Olof Björk

Ulrike Martini-Marr Ne&eacute; Martini

Sören Kulstad

Johansson Martin

Anke Mayer-Bartschmid Ne&eacute; Mayer

Jeanette Robertsson

Anke Mayer

Malgorzata Sznitowska

Marc Satadler

Rudong Shan

Rebecka Hellsten

Zilma Escobar

Ritha Gidlöf

Eduardo Muñoz

Annette Säfholm

Christer Sjögren

Lars Björk

Mogens Nielsen

Eduardo MUÑOZ

Pharmaceutical compositions and methods of using said pharmaceutical compositions are provided herein. A method of preventing preterm birth in a pregnant individual is also provided, said method comprising administering to said individual a pharmaceutical composition comprising a compound of Formula XX or a lactone thereof of formula XIX or XXI and preventing said preterm birth by said administration.

Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono &#x3b4;-lactone, wherein the glucono &#x3b4;-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono &#x3b4;-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Glucono delta-lactone for treatment of vaginal fungal infections

The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.

Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent. 

Sulfonamide analogues of galiellalactone

Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

Tricyclic prodrugs

The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.

Antimicrobial and antiinflammatory composition

Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed. The analogues are of formula (I) or (II): 

Ether analogues of galiellalactone

Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases. 

A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lactic acid is a trimer, HL, having n equal to 2, wherein the number average molecular weight Mof the oligomeric lactic acid is from about 200 to about 500, and ii) a mucoadhesive agent.

Pharmaceutical compositions containing oligomeric lactic acid

The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Use of oligomers of lactic acid in the treatment of gynaecological disorders

The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-&#x3ba;B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.

Tricyclic lactones for treatment of cancer

The disclosure describes compounds of formula I, wherein the wedged bonds, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier. 

Indolyl-substituted pyrazino[1,2-b]isoquinolines for cancer treatment

The invention relates to an oligomeric lactic acid composition comprising one or more oligomers of lactic acid or a pharmaceutical composition comprising an oligomeric lactic acid composition for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment.

The present invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAreceptor modulator. 

[object Object]

Growing community of inventors

Malmö, Sweden

Olov Sterner